EndoSonics stock hit hard by Q3 losses

Article

Disappointing European sales contributed to sharply lower than expected financial results for intravascular ultrasound developer EndoSonics. The Rancho Cordova, CA-based company reported revenues of $10.5 million for the third quarter (end-September 30),

Disappointing European sales contributed to sharply lower than expected financial results for intravascular ultrasound developer EndoSonics. The Rancho Cordova, CA-based company reported revenues of $10.5 million for the third quarter (end-September 30), down 10.3% compared with the $11.7 million posted for the same quarter a year ago. The company also realized a net loss of $3.2 million, compared with a net loss of $10.5 million (after acquisition and restructuring charges) last year. Without the charges, EndoSonics had a net income of $1.2 million in 1998.

This quarter’s revenues were lower than expected due to a substantial decline in orders from European distributor Jomed International and slower than anticipated sales in other foreign markets, according to Reinhard Warnking, EndoSonics president and CEO. As a result, the company has terminated one of its two distribution agreements with Jomed and will begin expanding its direct sales efforts. EndoSonics has already begun selling directly into the German market and now plans to do the same in certain other European countries.

Wall Street reacted quite negatively to the company’s financial news. EndoSonics’s stock dropped $4.41 following the announcement, shedding more than half of its value to land at $4.09 on Oct. 4. Analysts had expected the company to report a healthy profit in the third quarter.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.